Skip to contents

Aaron S. Kesselheim, MD, JD, MPH
Associate Physician, Brigham and Women's Hospital
Associate Professor of Medicine, Harvard Medical School

Brigham and Women's Hospital
Department of Medicine
Phar Epid & Phar Econ
75 Francis Street
Boston, MA 02115

Research Location: One Brigham Circle

Edit Profile

Research Narrative:
Aaron S. Kesselheim, MD, JD, MPH, is an Associate Professor of Medicine at Harvard Medical School and a faculty member in the Division of Pharmacoepidemiology and Pharmacoeconomics in the Department of Medicine at Brigham and Women’s Hospital. Within the Division, Dr. Kesselheim leads the Program On Regulation, Therapeutics, And Law (PORTAL), an interdisciplinary research core focusing on intersections among prescription drugs and medical devices, patient health outcomes, and regulatory practices and the law. Dr. Kesselheim is a Greenwall Faculty Scholar in Bioethics and is also supported by the Laura and John Arnold Foundation and the Harvard Program in Therapeutic Science. PORTAL conducts research on empirical and normative research in legal, ethical, and policy issues regarding the development, approval, and evidence-based use of drugs, devices, vaccines, procedures, and diagnostics. Particular areas of focus include regulation, intellectual property, and comparative effectiveness. These topics are addressed through a variety of descriptive, qualitative, and quantitative methodologies.

Harvard School of Public Health, 2007, MPH
University of Pennsylvania School of Medicine, 2002, MD
University of Pennsylvania Law School, 2002, JD

Publications (Pulled from Harvard Catalyst Profiles):

1. Desai RJ, Sarpatwari A, Dejene S, Khan NF, Lii J, Rogers JR, Dutcher SK, Raofi S, Bohn J, Connolly JG, Fischer MA, Kesselheim AS, Gagne JJ. Comparative effectiveness of generic and brand-name medication use: A database study of US health insurance claims. PLoS Med. 2019 Mar; 16(3):e1002763.

2. Bourgeois FT, Graham DA, Kesselheim AS, Randolph AG. Cost Implications of Escalating Intravenous Acetaminophen Use in Children. JAMA Pediatr. 2019 Mar 11.

3. Darrow JJ, Beall RF, Kesselheim AS. The Generic Drug Industry Embraces a Faster, Cheaper Pathway for Challenging Patents. Appl Health Econ Health Policy. 2019 Feb; 17(1):47-54.

4. Kesselheim AS, Woloshin S, Lu Z, Tessema FA, Ross KM, Schwartz LM. Internal Medicine Physicians' Financial Relationships with Industry: An Updated National Estimate. J Gen Intern Med. 2019 Feb; 34(2):195-197.

5. Hwang TJ, Bourgeois FT, Franklin JM, Kesselheim AS. Impact Of The Priority Review Voucher Program On Drug Development For Rare Pediatric Diseases. Health Aff (Millwood). 2019 Feb; 38(2):313-319.

6. Kesselheim AS, Woloshin S, Lu Z, Tessema FA, Ross KM, Schwartz LM. Physicians' Perspectives on FDA Approval Standards and Off-Label Drug Marketing. JAMA Intern Med. 2019 Jan 22.

7. Sarpatwari A, Gagne JJ, Lu Z, Campbell EG, Carman WJ, Enger CL, Dutcher SK, Jiang W, Kesselheim AS. A Survey of Patients' Perceptions of Pill Appearance and Responses to Changes in Appearance for Four Chronic Disease Medications. J Gen Intern Med. 2019 Mar; 34(3):420-428.

8. Rogers JR, Sarpatwari A, Desai RJ, Bohn JM, Khan NF, Kesselheim AS, Fischer MA, Gagne JJ, Connolly JG. Effect of Lawyer-Submitted Reports on Signals of Disproportional Reporting in the Food and Drug Administration's Adverse Event Reporting System. Drug Saf. 2019 01; 42(1):85-93.

9. Sarpatwari A, Barenie R, Curfman G, Darrow JJ, Kesselheim AS. The US Biosimilar Market: Stunted Growth and Possible Reforms. Clin Pharmacol Ther. 2019 Jan; 105(1):92-100.

10. Mundkur ML, Franklin J, Huybrechts KF, Fischer MA, Kesselheim AS, Linder JA, Landon J, Patorno E. Changes in Outpatient Use of Antibiotics by Adults in the United States, 2006-2015. Drug Saf. 2018 12; 41(12):1333-1342.